CYTO Stock Overview
Operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Altamira Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.42 |
| 52 Week High | US$17.20 |
| 52 Week Low | US$0.40 |
| Beta | 2.44 |
| 11 Month Change | -16.90% |
| 3 Month Change | -53.66% |
| 1 Year Change | -92.53% |
| 33 Year Change | -99.94% |
| 5 Year Change | -99.93% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID
Sep 13Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio
Aug 30Altamira starts development program for potential arthritis therapy
Jul 25Altamira announces peer-reviewed publication on mRNA delivery platform
Jul 19Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform
Jul 12Auris Medical shares rise on OligoPhore Lymphoma study results
Jun 21Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Jun 01Auris Medical updates on pollen challenge study for nasal spray
May 10Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?
Dec 09
Auris Medical prices $8M direct equity offering, stock -22%
Dec 02Shareholder Returns
| CYTO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.1% | 1.6% | 2.2% |
| 1Y | -92.5% | 9.9% | 31.6% |
Return vs Industry: CYTO underperformed the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: CYTO underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| CYTO volatility | |
|---|---|
| CYTO Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CYTO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CYTO's weekly volatility has decreased from 32% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 10 | Thomas Meyer | altamiratherapeutics.com |
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
Altamira Therapeutics Ltd. Fundamentals Summary
| CYTO fundamental statistics | |
|---|---|
| Market cap | US$1.44m |
| Earnings (TTM) | -US$7.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs CYTO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYTO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.91m |
| Earnings | -US$7.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CYTO perform over the long term?
See historical performance and comparison